Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.
Did you mean: ➙ act deep b cell?

VCU Collaboration Launched by Galmed Pharmaceuticals to Address Drug Resistance in GI Cancers

Galmed Pharmaceuticals Ltd. a clinical-stage biopharmaceutical company, announced a sponsored research collaboration with Virginia Commonwealth University (VCU) to investigate Aramchol's potential in overcoming drug resistance in gastrointestinal...

Exicure, Inc. (Nasdaq: XCUR) Unveils Next Steps Toward New Clinical Trial in Acute Myeloid Leukemia (AML)

Exicure, Inc. today shared updates on its lead asset, GPC-100 (burixafor), a small molecule CXCR4 inhibitor. Exicure, Inc. (“Exicure”) is planning for a clinical trial in Acute Myeloid Leukemia (AML) with GPC-100. The company believes that...

Novotech receives new investment from GIC, Temasek, and existing investor TPG to accelerate global growth

Novotech, a globally recognized full-service biotech specialist clinical research organization (CRO), announced today that affiliates of GIC and Temasek have signed binding agreements to acquire a significant stake in the company, with the...

SciTech Development announces the second FDA approval of a Phase 1 A/B IND for ST-001, which now targets the treatment of relapsed/refractory small cell lung cancer, following its previous approval for the treatment of T-cell NHL

SciTech Development, Inc., a clinical-stage oncology company pioneering innovative cancer therapeutics, is thrilled to announce that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for "A...

IRBM Expands Functional Genomics Platform for Early Drug Discovery

IRBM, an integrated Contract Research Organization (CRO) specializing in preclinical drug discovery, has established a comprehensive Functional Genomics Platform to support genetic target identification and validation, and generation of...

Developing innovative production technology for the commercialization of 3D cell products, PHC and Cyfuse collaborate

PHC Corporation a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. announce the successful development of a new production technology(*1) for the commercialization of...

Actinium Pharmaceuticals publishes Actimab-A + CLAG-M trial results for relapsed/refractory AML in Leukemia

Actinium Pharmaceuticals, Inc. a pioneer in the development of targeted radiotherapies, announced that results from the clinical trial evaluating Actimab-A in combination with the chemotherapy CLAG-M in patients with relapsed/refractory acute...

A convenient and cost-effective way to treat sickle cell disease may be offered by Vascarta's patented transdermal drug candidate

An article in the Proceedings of the National Academy of Sciences (PNAS) Nexus journal* by Goel et al. describes studies in which humanized sickle cell mice topically treated with Vascarta's transdermal curcumin gel formulation ("VAS-101")...

PointClickCare Integration Announced by AccessDx Laboratory

AccessDx Laboratory, a nationwide provider of precision medicine and diagnostics solutions, today announced its expanded integration with PointClickCare, a leading healthcare technology platform enabling meaningful care collaboration and real-time...

Fosun Pharma deeply embraces AI, with its self-developed PharmAID Decision Intelligence Platform boosting efficient innovation

Nowadays, artificial intelligence (AI) technology is profoundly reshaping the landscape of the pharmaceutical and healthcare industry. As a global innovation-driven pharmaceutical and healthcare group, Fosun Pharma places great emphasis on the...

Legacy Pharmacy Group (LPG) and Independent Pharmacy Cooperative (IPC) announce a strategic cooperation agreement

Independent Pharmacy Cooperative (IPC), the leading Group Purchasing Organization (GPO) for independent pharmacies nationwide, is thrilled to announce a groundbreaking cooperation agreement with Legacy Pharmacy Group (LPG). This strategic...

Harbour BioMed receives NMPA IND clearance for HBM9378/SKB378 in treating chronic obstructive pulmonary disease

Harbour BioMed a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immunology, announced that the National Medical Products Administration...

HOOKIPA Pharma announces the completion of enrollment in its Phase 1b clinical trial evaluating HB-500 for the treatment of HIV

HOOKIPA Pharma Inc. a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced that enrollment is complete in the Phase 1b clinical trial...

The merger with NLS Pharmaceutics was approved by Kadimastem shareholders

NLS Pharmaceutics Ltd. a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem Ltd. ("Kadimastem") (TASE: KDST), a...

Artax Biopharma validates AX-158, a first-in-class oral Nck modulator, in phase 2a for autoimmune disease

Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, today announces achievement of clinical validation through its Phase 2a clinical trial in psoriasis with fully proprietary...

SeoulTech researchers unveil a novel approach to understanding PFOS-induced neurotoxicity, advancing environmental health studies

The term "omics" refers to the study of entirety of molecular mechanisms happening inside an organism. With the advent of omics technologies like transcriptomics, proteomics, metabolomics, and lipidomics, our understanding of molecular pathways of...

Chromatin Bioscience's synthetic promoter enables EsoBiotec's ESO-T01 CAR-T therapy to progress to clinical trials

Chromatin Bioscience is pleased to announce its ongoing collaboration with EsoBiotec, which has successfully advanced its ESO-T01 in vivo CAR-T candidate into clinical trials. ESO-T01 is the first in vivo B-cell maturation antige. (BCMA) CAR-T...

Matthew Fyfe has been appointed as Chief Scientific Officer as Outrun Therapeutics expands its leadership team

Outrun Therapeutics ("Outrun"), the E3 ligase inhibitor and protein stabilisation specialist, announces the appointment of Matthew Fyfe as its Chief Scientific Officer. Matthew has over 25 years' experience in drug discovery and development across...

Ouro Medicines launches to transform treatment for immune-mediated diseases with innovative therapies

Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, today announced its launch with $120 million in funding. The company was founded by Monograph Capital in...

Mediar Therapeutics partners with Lilly to develop a first-in-class WISP1 antibody for idiopathic pulmonary fibrosis

Mediar Therapeutics, Inc., a clinical stage biotechnology company advancing a portfolio of first-in-class therapies designed to halt fibrosis progression, announced a global licensing agreement with Eli Lilly and Company to advance MTX-463 into a...

Results 81 - 100 of 139